Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
Last trade$1.42
Day change-$0.065 (-4.39%)
Day range$1.41 – $1.55
Volume947,314
Market cap$67M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$67.39M
Price / earnings
—
Price / book
0.62×
Price / sales
—
EV / sales
—
EV / EBITDA
0.67×
Profitability
Earnings per share
-$1.44
Return on assets
-56.2%
Return on equity
-60.52%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
14.01×
Quick ratio
14.01×
Cash ratio
13.61×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$49.35M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TENX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$5.66M
$5.93M
$5.03M
$5.91M
$6.48M
$5.67M
$5.66M
$2.7M
Research and development
$12.07M
$12.85M
$11.54M
$10.54M
$10.33M
$6.12M
$5.68M
$4.59M
Total operating expenses
$17.73M
$18.78M
$16.57M
$16.45M
$16.81M
$11.79M
$11.34M
$7.3M
Operating income
-$17.73M
-$18.78M
-$16.57M
-$16.45M
-$16.81M
-$11.79M
-$11.34M
-$7.3M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$1K
Income before taxes
-$16.7M
-$17.8M
-$15.72M
-$15.54M
-$15.8M
-$10.85M
-$10.41M
-$6.27M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$16.7M
-$17.8M
-$15.72M
-$15.54M
-$15.8M
-$10.85M
-$10.41M
-$6.27M
Net income attributable to common shareholders
-$16.7M
-$17.8M
-$15.72M
-$15.54M
-$15.8M
-$10.85M
-$10.41M
-$6.27M
EBITDA
-$17.73M
-$18.78M
-$16.57M
-$16.45M
-$16.81M
-$11.79M
-$11.34M
-$7.3M
Basic earnings per share
-$0.31
-$0.35
-$0.35
-$0.38
-$0.40
-$0.27
-$0.28
-$0.17
Diluted earnings per share
-$0.31
-$0.35
-$0.35
-$0.38
-$0.40
-$0.27
-$0.28
-$0.17
Recent news
Company coverage with links to the original publishers.
Bronstein Gewirtz & Grossman, LLC has announced class action lawsuits against Tenax Therapeutics and Kinross Gold Corporation for alleged securities fraud. Tenax investors who purchased securities between November 13, 2023 and August 7, 2026 may be eligible to recover losses, with a lead plaintiff deadline of December 28, 2026. The lawsuit alleges that Tenax made materially false statements regarding its lead clinical program TNX-103's effectiveness and commercial prospects.
A class action lawsuit has been filed against Tenax Therapeutics for alleged securities fraud. The complaint alleges that the company made materially false and misleading statements regarding its lead clinical program TNX-103, overstating its effectiveness and commercial prospects. Investors who purchased Tenax securities between November 13, 2023 and August 7, 2026 may be eligible to recover losses, with a lead plaintiff deadline of December 28, 2026.
Tenax Therapeutics received an upgrade to Zacks Rank #2 (Buy) driven by upward revisions in earnings estimates over the past three months, with a 6.1% increase in consensus estimates. The company is positioned in the top 20% of Zacks-covered stocks based on earnings estimate revisions, suggesting potential near-term stock price appreciation.
Several class action lawsuits have been filed against publicly traded companies alleging securities fraud and violations of federal securities laws. Endava plc faces allegations of false statements regarding accounting treatment and internal control effectiveness. Additional lawsuits target Tenax Therapeutics, D-Wave Quantum, FuelCell Energy, Lincoln Educational Services, and Baidu, with various lead plaintiff deadlines in November and December 2026.
Several class action lawsuits have been filed against publicly traded companies alleging securities fraud and misleading statements to investors. Tenax Therapeutics faces claims regarding overstated effectiveness of its lead clinical program TNX-103. Additional lawsuits target D-Wave Quantum, Compass Inc., FuelCell Energy, Lincoln Educational Services, and Baidu, with various lead plaintiff deadlines in November and December 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.